Company Analysis
Sign in

Prime Medicine, Inc. (PRME)

Nasdaq: PRME · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.1
◀ Past 3.7● Present 3.0▶ Future 5.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 3, 2026Feb 28, 2025Mar 1, 2024Mar 9, 2023··
Revenue4,6322,9830005,210
Research and development160,636155,289147,90586,72570,5502,980
General and administrative52,34650,16143,38729,81913,9243,162
Total operating expenses212,982205,450204,792116,54484,4746,142
Operating income-208,350-202,467-204,792-116,544-84,474-932
Interest and investment income4,1493,5222,811···
Other income (expense), net14841274r1,90312126
Total non-operating income (expense)7,2086,5856,380-6,225-81,379-611
Income tax expense00-279-948-4861,867
Net income-201,142-195,882-198,133-121,821-165,367-3,410
Preferred dividends··020,19317,2840
Net income to common shareholders-201,142-195,882-198,133-142,014-184,119-5,055
Earnings per share, basic-1.35-1.65-2.18-4.19-14.19-1.91
Earnings per share, diluted-1.35-1.65-2.18-4.19-14.19-1.91
Weighted average shares, basic148,758,527118,600,38190,969,32733,891,26412,973,4952,639,717
Weighted average shares, diluted148,758,527118,600,38190,969,32733,891,26412,973,4952,639,717
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Preferred dividends paid to preferred holders before common shareholdersus-gaap:PreferredStockDividendsIncomeStatementImpact
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton PRME · research, not advice